CollPlant Biotechnologies (CLGN) Liabilities and Shareholders Equity (2017 - 2025)

CollPlant Biotechnologies' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $10.8 million for Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 42.36% year-over-year to $10.8 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $42.3 million (down 6.6% YoY) and the FY2025 annual result came in at $10.8 million, down 42.36% from the prior year.
• Liabilities and Shareholders Equity was $10.8 million for Q4 2025 at CollPlant Biotechnologies, down from $14.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $55.0 million in Q2 2021 and bottomed at $22442.0 in Q3 2024.
• A 5-year average of $27.9 million and a median of $34.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 85931.36% — and 2024, when it tumbled 99.92%.
• CollPlant Biotechnologies' Liabilities and Shareholders Equity stood at $51.2 million in 2021, then declined by 26.27% to $37.8 million in 2022, then decreased by 9.64% to $34.1 million in 2023, then slumped by 45.17% to $18.7 million in 2024, then plunged by 42.36% to $10.8 million in 2025.
• Business Quant data shows CLGN's Liabilities and Shareholders Equity at $10.8 million in Q4 2025, $14.1 million in Q3 2025, and $17.4 million in Q2 2025.